Taysha Gene Therapies Q2 net loss widens on higher R&D costs

The current average analyst rating on the shares is buy, with 12 strong buy or buy recommendations, no hold ratings and no sell or strong sell ratings.

The average consensus recommendation for the biotechnology and medical research peer group is buy. Wall Street's median 12-month price target for Taysha Gene Therapies is $12.50, about 96.2% above its August 10 closing price of $6.37.

The company said it expects topline data from the REVEAL pivotal trial and FDA feedback in the first half of 2027.

Taysha projects cash runway into the second half of 2028 and through potential BLA approval of TSHA-102. The company said it is advancing commercial readiness activities for a potential TSHA-102 launch if approved.

Taysha also completed a $230 million follow-on offering, which it said extended its cash runway into the second half of 2028.

Taysha Gene Therapies reported no second-quarter revenue and a wider net loss year over year as operating expenses rose, driven by manufacturing and clinical trial costs for TSHA-102.